Conventional CRISPR nucleases, including Cas9 and Cas12a ... Existing compact systems like Cas14 and IscB have not ...

and SaCas9 (Cas9 nuclease from Staphylococcus aureus), which are commonly used in CRISPR. Both of them have a certain level of imprecision or off-target effect. Researchers have already engineered ...

Published on Nature Communications, this CRISPR-Cas9 system, originated from Campylobacter jejuni (CjCas9), is expected to become a useful therapeutic tool against common and "undruggable" disease ...

Researchers have developed a new variant of the gene editing technique CRISPR-Cas9 that ... Another version, the Cas9 nuclease from the bacteria Staphylococcus aureus (SaCas9), is much smaller ...

There are currently two versions of the Cas9 enzyme commonly adopted in CRISPR research: SpCas9 (Cas9 nuclease from the bacteria Streptococcus pyogenes) and SaCas9 (Cas9 nuclease from Staphylococcus ...

A new paper points to a previously unknown hurdle for scientists racing to develop therapies using the revolutionary genome-editing tool CRISPR-Cas9 ... aureus (called SaCas9) and those from ...

When the CRISPR Cas9 protein is added to a cell along with a piece of guide RNA, the Cas9 protein hooks up with the guide RNA and then moves along the strands of DNA until it finds and binds to a ...

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.